Skip to main content
. 2003 Jul 1;89(1):8–14. doi: 10.1038/sj.bjc.6601035

Table 2. Summary of changes in angiogenic factors compared with patient outcome.

Agent Pata Outcome Fluidb VEGF bFGF VCAM-1 v-WF Thmc Esel uPAsr MMP-2 MMP8 MMP9 TIMP1 TIMP2
Razoxane 35 StD(11) U, P, S (56) S, Pre PD>StDd S, Post PD>StDd S, Post PD>StDd S, Pre PD>StDd     P, Pre PD>StDd          
        U, PD Pre vs Poste U, Pre PD>StDd S, PD Pre vs Poste S, Post PD>StDd     P, Post PD>StDd          
MM1270 75 StD(19) P(28) Nc w/AUCe Nc         w/AUCe Nc W/Cmaxe W/AUCe W/AUCe
BAY 12-9566 21 No response P(29)               Nc   Nc   Post>Pre
COL-3 35 StD(8) S, P(28) S, Nc S, Nc           P, Post PD>StD   P, Nc    
Endostatin 25 StD(1), MR(1) S(28,56) Nc Nc Nc     Nc            
TNP-470 12 No response U, S(28)   Nc     S, Nc Nc            
SU5416 22 StD(3), MR(1) U(36) Pre>Poste Nc                    
Thalidomide 16 PR(2), MR(2), StD(12) S, U(56) Nc S, Decreased, U, Nc                    
a

Patients studied.

b

P=Plasma, S=Serum, U=Urine (days post-treatment).

c

Thrombomodulin.

d

Significant differences.

e

Significant increase. Nc=no significant change; Pre=before treatment; Post=after treatment; PD=progressive disease; StD=stable disease; MR=minor response; PR=partial response; AUC=area under concentration curve.